Posted in M&A / Deals UCB to purchase Neurona and NRTX-1001 for $1.15bn April 20, 2026 Pharmaceutical Technology UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio. M&A / DealsNeuroscienceRead full story